The Neuroscience Journal of Shefaye Khatam
مجله علوم اعصاب شفای خاتم
Shefaye Khatam
Medical Sciences
http://shefayekhatam.ir
1
admin
2322-1887
2345-4814
10.61186/shefa
fa
jalali
1395
11
1
gregorian
2017
2
1
4
4
online
1
fulltext
fa
P12: Cell Therapies for Neurological Injury
P12: Cell Therapies for Neurological Injury
تحقیقات پایه در علوم اعصاب
Basic research in Neuroscience
مروری
Review --- Open Access, CC-BY-NC
<p style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: Tahoma; font-size: 12px; text-align: center; background-color: rgb(251, 250, 249);">لطفاً به چکیده انگلیسی مراجعه شود.</span></p>
<p>A neurological disorder is any <a href="https://en.wikipedia.org/wiki/Disorder_(medicine)#Disorder" title="Disorder (medicine)">disorder</a> of the <a href="https://en.wikipedia.org/wiki/Nervous_system" title="Nervous system">nervous system</a> is usually due to cell loss. The ultimate goal of CNS therapy is to replace lost cells and tissue. There is no neuroprotective, pharmacological and effective treatment available that restores the injury-induced loss of function. Recent studies suggest that identification of adult neural stem/progenitor cells indwelling in the neurogenic regions in the adult mammalian brain and spinal cord may play regenerative and reparative roles in response to CNS injuries. Therefore, cell transplantation is a potential strategy to repair and regenerate the injured brain and spinal cord. Different types of stem cells vary in their ability to help restore function, and an ideal treatment protocol remains unclear pending further clinical research. Stem cells derived from adult tissues such as mesenchymal progenitor cells, fetal progenitors, and post-mitotic cells have a limited potential to differentiate into specific cell types. As Brain and spinal cord injury are associated with enormous loss of multiple cell types due to primary mechanical tissue disruption. The choice of stem cell population used in replacement therapies after Brain and spinal cord injury might therefore be critical.</p>
Neurological injury, Cell therapies, Neural stem/progenitor cells
34
34
http://shefayekhatam.ir/browse.php?a_code=A-10-24-803&slc_lang=fa&sid=1
Sara
Abdolahi
Sara
Abdolahi
abdolahisara65@gmail.com
100319475328460011400
100319475328460011400
Yes
a. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran b. Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
a. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran b. Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
Sedigheh
Ghasemi
Sedigheh
Ghasemi
100319475328460011401
100319475328460011401
No
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
Robabeh
Jafari
Robabeh
Jafari
100319475328460011402
100319475328460011402
No
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
Zeinab
Najmi
Zeinab
Najmi
100319475328460011403
100319475328460011403
No
a. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran b. Microbial biotechnology Group, Faculty of Basic Sciences, Tehran Science and Research Branch, Islamic Azad University, Tehran, Iran
a. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran b. Microbial biotechnology Group, Faculty of Basic Sciences, Tehran Science and Research Branch, Islamic Azad University, Tehran, Iran